Holen Sie sich die Stockscreener-App
38.08
1.70%
-0.66
Handel nachbörslich:
38.08
Schlusskurs vom Vortag:
$38.74
Offen:
$38.28
24-Stunden-Volumen:
1.21M
Relative Volume:
1.37
Marktkapitalisierung:
$3.01B
Einnahmen:
$399.58M
Nettoeinkommen (Verlust:
$-54.04M
KGV:
-50.77
EPS:
-0.75
Netto-Cashflow:
$40.13M
1W Leistung:
-9.91%
1M Leistung:
-9.93%
6M Leistung:
+58.87%
1J Leistung:
-17.47%
1-Tages-Spanne:
$37.33
$38.44
1-Wochen-Bereich:
$37.33
$42.64
52-Wochen-Spanne:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Firmenname
Veracyte Inc
Sektor
Branche
Telefon
(650) 243-6300
Adresse
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie VCYT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
38.08 | 3.06B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
578.61 | 222.48B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
218.89 | 155.25B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
670.46 | 54.04B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
230.15 | 40.13B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.85 | 37.78B | 6.95B | 1.30B | 1.15B | 4.5696 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Underweight |
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Hold |
| 2025-03-20 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-16 | Eingeleitet | UBS | Buy |
| 2024-10-10 | Eingeleitet | Guggenheim | Buy |
| 2024-02-23 | Bestätigt | Needham | Buy |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-11-18 | Fortgesetzt | Goldman | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Outperform |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2019-07-31 | Eingeleitet | Lake Street | Buy |
| 2019-07-02 | Eingeleitet | Needham | Buy |
| 2018-11-29 | Herabstufung | Janney | Buy → Neutral |
| 2018-10-31 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-07 | Herabstufung | Janney | Buy → Neutral |
| 2017-11-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Fortgesetzt | BTIG Research | Buy |
| 2016-11-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-18 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-11 | Bestätigt | Leerink Partners | Outperform |
| 2013-11-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Veracyte Inc Aktie (VCYT) Neueste Nachrichten
Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now - Finviz
Can Veracyte Inc. ride the EV waveQuarterly Portfolio Report & Precise Buy Zone Identification - mfd.ru
Earnings Miss: Can Veracyte Inc expand into new marketsEarnings Summary Report & Fast Moving Market Watchlists - baoquankhu1.vn
Veracyte, Inc. (VCYT) Stock Analysis: A Diagnostic Leader With 17.49% Potential Upside - DirectorsTalk Interviews
Veracyte, Inc. (VCYT) sees analyst support as Guggenheim reaffirms buy rating - MSN
Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again - primepublishers.com
Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate - Chartmill
Stronger‑Than‑Expected Revenue Outlook Might Change The Case For Investing In Veracyte (VCYT) - simplywall.st
Swing Trade: What is the dividend yield of TriSalus Life Sciences Inc Equity WarrantJuly 2025 WrapUp & Verified Entry Point Signals - baoquankhu1.vn
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Assessing Veracyte (VCYT) Valuation As Recent Momentum Meets An Expensive P/E Ratio - Sahm
Is Veracyte’s (VCYT) Confident Double‑Digit Revenue Outlook Altering The Investment Case For Investors? - Yahoo Finance
Veracyte, Inc. (VCYT) Sees Analyst Support as Guggenheim Reaffirms Buy Rating - Finviz
Centene Expands Palliative Care Access in Ohio Through Tuesday Health - Nasdaq
QRG Capital Management Inc. Sells 106,926 Shares of Veracyte, Inc. $VCYT - MarketBeat
S P Trends: Is Veracyte Inc showing insider buyingTrade Entry Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
State of Alaska Department of Revenue Takes $1.50 Million Position in Veracyte, Inc. $VCYT - MarketBeat
Trade Recap: Is Veracyte Inc stock a value trapJuly 2025 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Veracyte: Profitable, De-Risked, And Ready To Run (NASDAQ:VCYT) - Seeking Alpha
Sumitomo Mitsui Trust Group Inc. Sells 165,094 Shares of Veracyte, Inc. $VCYT - MarketBeat
SG Americas Securities LLC Increases Stock Position in Veracyte, Inc. $VCYT - MarketBeat
Veracyte (NASDAQ:VCYT) Cut to Hold at Zacks Research - MarketBeat
Is Veracyte’s 2026 Growth Guidance And New US Launches Altering The Investment Case For Veracyte (VCYT)? - Sahm
Louisiana State Employees Retirement System Invests $1.24 Million in Veracyte, Inc. $VCYT - MarketBeat
Lung Cancer Diagnostics Market Size and Forecast 2025–2033 - Vocal
Breakout Move: What is the dividend yield of CMMBJuly 2025 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
Volume Recap: Is Veracyte Inc. stock a top pick in earnings seasonStock Surge & Accurate Trade Setup Notifications - Bộ Nội Vụ
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $44 - 富途牛牛
Morgan Stanley initiates coverage of Veracyte, Inc. (VCYT) - MSN
Veracyte stock rating reiterated at Buy by UBS on strong revenue outlook - Investing.com Australia
Veracyte stock rating reiterated at Buy by UBS on strong revenue outlook By Investing.com - Investing.com India
Needham reiterates Buy rating on Veracyte stock after strong Q4 preannouncement - Investing.com Nigeria
Summit Creek Advisors LLC Makes New $8.52 Million Investment in Veracyte, Inc. $VCYT - MarketBeat
Veracyte stock outlook positive as Leerink reiterates Outperform rating By Investing.com - Investing.com South Africa
Veracyte stock outlook positive as Leerink reiterates Outperform rating - Investing.com India
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results - 01net
Veracyte (VCYT) Sets Ambitious Revenue Growth Targets for 2026 - GuruFocus
Veracyte (VCYT) Poised for Growth with New Product Launches in 2 - GuruFocus
BRIEF-Veracyte Outlook FY Revenue Growth 16% - TradingView — Track All Markets
Published on: 2026-01-11 01:59:58 - ulpravda.ru
Veracyte Reports Strong Q3 2025 Financial Performance - MSN
Market Wrap: Can Veracyte Inc 12V stock reach 200 price targetJuly 2025 Final Week & Precise Buy Zone Identification - Bộ Nội Vụ
Can Veracyte Inc. (12V) stock reach $200 price targetJuly 2025 Weekly Recap & AI Driven Price Predictions - Улправда
Veracyte, Inc. (NASDAQ:VCYT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Why Veracyte Inc. stock could outperform in 2025July 2025 Decliners & Low Risk Growth Stock Ideas - Улправда
Finanzdaten der Veracyte Inc-Aktie (VCYT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):